Company profile / JAZZ

Jazz Pharmaceuticals

Clinaptis stanceCautious

ConvictionMedium

Ticker: JAZZ
Exchange: NASDAQ
Coverage: Standard profile
Updated: Aug 19, 2026

Neurology / Oncology

Global biopharmaceutical company focused on developing and commercializing medicines for sleep disorders, neurology, and oncology conditions.

01 / Clinaptis view

The current read

Stable neuroscience base business (Xywav, Sunosi) provides cash flow to fund high-potential oncology pipeline, though patent cliffs require successful new product transitions.

02 / Consensus gap

Where the market may differ

Oncology pipeline probability of success vs. near-term neuroscience revenue erosion.

Coverage state: Standard profile

What the review turns on

Key variable

Pipeline replacement value

Next catalyst

Modeyso (dordaviprone) · ACTION confirmatory trial data (newly diagnosed) · 2026

03 / Pipeline

Key programs

2 assets · 2 programs

AssetIndicationStageNext event

Modeyso (dordaviprone)

Recurrent H3 K27M-mutant diffuse midline glioma

Commercial

ACTION confirmatory trial in newly diagnosed patients

Xywav / Sunosi

Idiopathic hypersomnia / Narcolepsy

Commercial

Ongoing market share expansion

04 / Connected research

Published on JAZZ

View full archive

No published research attached

The profile is live. The research connection is still open.

When a Clinaptis article includes JAZZ in its research metadata, it will appear here automatically.

Browse all research